Please find enclosed herewith Intimation of One of One Meet.
Please find enclosed herewith Intimation of One on One Meet.
Please find enclosed herewith Intimation of One on One Meet.
Alembic Pharmaceuticals Limited received USFDA Tentative Approval for Binimetinib Tablets, 45 mg.
Appointment of Mr. Sujit Bhayani as Non-Executive Independent Director of the Company w.e.f. 18th June, 2026.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Tretinoin Cream USP, 0.05%.
Please find enclosed herewith the Intimation regarding re-affirmation of credit rating on Commercial Paper
Please find enclosed.
Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for Larotrectinib Capsules, 25 mg and 100 mg.
Please find enclosed.
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,486.15 | 1,594.93 | 1,630.57 | 1,516.98 | 1,561.73 | 1,647.98 | 1,692.74 | 1,769.64 | 1,710.72 | 1,910.15 | 1,876.31 | 1,847.72 |
| YOY Revenue Growth % | 17.75% | 8.13% | 8.05% | 7.86% | 5.09% | 3.33% | 3.81% | 16.66% | 9.54% | 15.91% | 10.84% | 4.41% |
| Other Income | 11.67 | 10.15 | 2.89 | 3.60 | 2.10 | 16.75 | 9.50 | 14.19 | 6.50 | 6.91 | 15.50 | 25.50 |
| Total Income | 1,497.81 | 1,605.09 | 1,633.46 | 1,520.58 | 1,563.83 | 1,664.72 | 1,702.25 | 1,783.83 | 1,717.22 | 1,917.06 | 1,891.81 | 1,873.22 |
| Total Expenses + | 1,368.03 | 1,469.94 | 1,448.83 | 1,337.34 | 1,407.12 | 1,498.03 | 1,524.82 | 1,591.22 | 1,526.67 | 1,694.76 | 1,686.24 | 1,730.94 |
| Cost of Materials Consumed | 334.19 | 413.87 | 317.58 | 337.38 | 405.93 | 393.14 | 446.91 | 426.20 | 431.27 | 463.14 | 448.73 | 404.24 |
| Employee Benefit Expense | 348.17 | 346.99 | 349.28 | 401.85 | 379.77 | 391.47 | 397.52 | 393.59 | 422.77 | 437.54 | 432.71 | 438.91 |
| Other Expenses | 525.77 | 578.26 | 554.16 | 475.70 | 551.04 | 588.13 | 595.46 | 573.51 | 599.20 | 641.00 | 621.13 | 648.74 |
| Operating Profit | 118.12 | 125.00 | 181.74 | 179.64 | 154.60 | 149.94 | 167.93 | 178.42 | 184.05 | 215.39 | 190.07 | 116.78 |
| OPM % | 7.9% | 7.8% | 11.1% | 11.8% | 9.9% | 9.1% | 9.9% | 10.1% | 10.8% | 11.3% | 10.1% | 6.3% |
| Profit Before Tax + | 129.79 | 135.15 | 184.63 | 183.24 | 156.71 | 179.56 | 177.43 | 192.61 | 190.55 | 222.30 | 163.34 | 117.52 |
| Tax Expense | 9.19 | -1.41 | 4.18 | 5.03 | 22.17 | 26.42 | 39.74 | 35.98 | 36.92 | 38.59 | 31.39 | -84.02 |
| Tax % | 7.1% | -1% | 2.3% | 2.7% | 14.1% | 14.7% | 22.4% | 18.7% | 19.4% | 17.4% | 19.2% | -71.5% |
| Profit After Tax | 120.60 | 136.56 | 180.46 | 178.21 | 134.54 | 153.15 | 137.70 | 156.63 | 153.63 | 183.71 | 131.95 | 201.54 |
| EPS (Basic) | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.79 | 7.01 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 7,344.90 | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 | 4,605.75 |
| YOY Revenue Growth % | 10.08% | 7.12% | 10.19% | 6.54% | -1.62% | 17.1% | - |
| Other Income | 54.41 | 42.55 | 28.31 | 2.74 | 50.46 | 10.02 | 4.94 |
| Total Income | 7,399.31 | 6,714.63 | 6,256.93 | 5,655.36 | 5,356.25 | 5,403.14 | 4,610.69 |
| Total Expenses + | 6,638.62 | 6,021.20 | 5,624.13 | 5,269.86 | 4,736.14 | 4,035.06 | 3,322.39 |
| Cost of Materials Consumed | 1,747.38 | 1,672.17 | 1,403.01 | 1,250.08 | 1,129.12 | 1,185.35 | 979.05 |
| Employee Benefit Expense | 1,731.93 | 1,562.34 | 1,446.30 | 1,169.13 | 1,133.00 | 1,051.17 | 906.44 |
| Other Expenses | 2,510.06 | 2,308.15 | 2,133.90 | 2,066.33 | 1,852.20 | 1,527.06 | 1,436.89 |
| Operating Profit | 706.28 | 650.88 | 604.50 | 382.76 | 569.65 | 1,358.07 | 1,283.36 |
| OPM % | 9.6% | 9.8% | 9.7% | 6.8% | 10.7% | 25.2% | 27.9% |
| Profit Before Exceptional | 760.69 | 693.43 | 632.81 | 385.51 | 620.11 | 1,368.08 | 1,043.48 |
| Exceptional Items | -66.98 | 12.87 | 0.00 | 0.00 | 0.00 | 0.00 | -43.65 |
| Profit Before Tax + | 693.71 | 706.30 | 632.81 | 385.51 | 620.11 | 1,368.08 | 999.83 |
| Tax Expense | 22.88 | 124.29 | 16.99 | 43.51 | 99.17 | 221.58 | 199.13 |
| Tax % | 3.3% | 17.6% | 2.7% | 11.3% | 16% | 16.2% | 19.9% |
| Profit After Tax | 670.83 | 582.01 | 615.82 | 341.99 | 520.94 | 1,146.50 | 800.70 |
| EPS (Basic) | 34.33 | 29.68 | 31.33 | 17.40 | 27.76 | 60.81 | 43.97 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Non-Current Assets + | 4,189.99 | 3,685.14 | 3,367.03 | 3,272.81 | 4,342.63 | 4,131.08 | 0.00 |
| Property, Plant & Equipment | 2,843.59 | 2,523.53 | 2,546.71 | 2,398.45 | 1,742.34 | 1,703.74 | 0.00 |
| Capital Work in Progress | 633.70 | 837.22 | 524.36 | 601.28 | 2,205.79 | 1,944.28 | 0.00 |
| Non-Current Investments | 113.17 | 101.49 | 68.61 | 71.20 | 63.69 | 0.45 | 0.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 237.08 | 0.00 | 0.00 | 0.00 | 56.38 | 85.56 | 0.00 |
| Current Assets + | 4,542.60 | 4,087.80 | 3,078.56 | 2,910.02 | 2,779.40 | 2,577.90 | 0.00 |
| Inventories | 2,510.64 | 2,288.14 | 1,643.54 | 1,475.27 | 1,609.70 | 1,486.15 | 0.00 |
| Trade Receivables | 1,466.30 | 1,399.79 | 1,024.84 | 1,046.40 | 807.13 | 348.58 | 0.00 |
| Cash and Cash Equivalents | 196.37 | 83.48 | 120.21 | 75.48 | 61.09 | 98.06 | 0.00 |
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.97 | 0.00 |
| LIABILITIES & EQUITY | |||||||
| Total Equity | 5,668.98 | 5,189.52 | 4,818.20 | 4,370.47 | 5,237.55 | 5,066.97 | 0.00 |
| Equity Share Capital | 39.31 | 39.31 | 39.31 | 39.31 | 39.31 | 39.31 | 0.00 |
| Other Equity | 5,635.50 | 5,151.63 | 4,778.89 | 4,331.16 | 5,198.23 | 5,088.30 | 0.00 |
| Non-Current Liabilities | 499.77 | 171.09 | 172.39 | 175.43 | 167.96 | 361.16 | 0.00 |
| Current Liabilities | 2,593.84 | 2,412.33 | 1,455.00 | 1,636.92 | 1,716.53 | 1,280.84 | 0.00 |
| Total Liabilities | 3,093.61 | 2,583.42 | 1,627.39 | 1,812.36 | 1,884.49 | 1,642.01 | 0.00 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activities | 782.73 | 87.97 | 803.20 | 723.95 | 552.30 | 1,463.38 | 0.00 |
| Cash from Investing Activities | -506.05 | -568.41 | -320.61 | -447.60 | -371.97 | -838.81 | 0.00 |
| Cash from Financing Activities | -163.79 | 443.71 | -437.87 | -261.97 | -217.30 | -597.43 | 0.00 |
| Net Increase/Decrease in Cash | 112.89 | -36.73 | 44.73 | 14.39 | -36.97 | 26.22 | 0.00 |